LINDAL Group will be showcasing its entire e spectrum of pharma packaging solutions at the CPhI Worldwide 2017 exhibition – Messe Frankfurt, Germany. Global businesses are invited to visit them in hall 4, stand 42D53 on the 24-26th October 2017.
LINDAL Group will be sharing expertise in pharma aerosol dispensing and systems, revealing the design and development of their pharma devices.
Gabriele Marchetti, Technical Sales Manager for LINDAL Group explained: “Aerosol technology is employed on various drug delivery systems that allows the transport of the medication in exact location in the body: Pulmonary, nasal and topical deliveries can be achieved by means of aerosol technology, since pressurized packs can generate fine particles able to reach the lungs, micronized or streamed fluids to irrigate the nose and foams or gels for skin absorption.Thanks to the latest innovations, food supplements and nutraceutical are also conveniently delivered by aerosol systems.”
LINDAL manufactures pharma metering valves for a wide range of applications supplying companies all over the world.
The KHFA valve is designed for CFC free formulation and the HFA is environmentally friendly. The valve has proven itself on suspension, solution and hybrid formulations, offering performance meeting the most demanding International specifications. The KHFA valve is compatible with a wide range of formulations with a clean extractable profile. There’s no need for priming due to the rapid fill/rapid drain technology. LINDAL’s large collection of pharma products includes Bag on Valves (BoV), the popular Pinocchio actuator for nasal applications and many other products such as gel, spray, foam and oil. Their aerosol technology can be used for pulmonary, nasal, topical and rectal delivery. Pain relief, skin treatments, hand sanitizing, nutraceutical and food supplements.
Additionally, Aptar Pharma, drug delivery systems provider, is pleased to once again be an exhibitor at CPhI Worldwide 2017, which takes place in Frankfurt, Germany from October 24–26.
This year, the Aptar Pharma booth, located at stand No. 42F10, Hall 4.2., will feature an innovation area showcasing seven healthcare technology megatrends, including a special connectivity hub, which will be dedicated to the growing field of connected healthcare solutions.
In addition to exhibiting at CPhI Worldwide, Aptar Pharma will present three Pharma Insight Briefings that will highlight its latest innovations and developments in the following drug delivery system areas:
Innovative Respiratory Solutions for Expanding Your Product Portfolio
Guenter Nadler, Director Business Development at Aptar Pharma, will deliver an insightful talk on innovative respiratory solutions on the first day of CPhI Worldwide. As a global rise in allergies and air pollution have led to a significant increase in upper respiratory tract diseases, typical over-the-counter medications and household remedies cannot always fulfill the needs of today’s on-the-go lifestyle.
Guenter Nadler’s Pharma Insight Briefing will take place on Tuesday, October 24 at 10:30 at the Innopack Zone, G1A3.
Driving Better Patient Outcomes with Connectivity
Sai Shankar, Director Business Development – Connected Devices, will present Aptar Pharma’s second Pharma Insight Briefing at CPhI Worldwide.
Using a patient-centric design approach, Aptar Pharma supports Pharma companies worldwide with custom-made solutions, including connected technologies, for the treatment of respiratory diseases including asthma and COPD. The findings of a study recently conducted by Aptar Pharma on its integrated connected pMDI, as well as the company’s connected health devices portfolio that support respiratory treatment for patients, will be among the topics presented at this briefing.
Sai Shankar’s Pharma Insight Briefing will take place on Tuesday, October 24 at 15:50 at the Innopack Zone, G1A3.
Setting New Standards for Coated Stoppers
Arnaud Fournier, Senior Business Project Manager for Injectables at Aptar Pharma, will exclusively introduce PremiumCoat™, a coated stopper which represents a step change in the provision of elastomeric stoppers with a market leading reduction in particulates, and is Aptar Pharma’s response to the growing challenges to developing more sensitive drugs in the pharmaceutical market.
Arnaud Fournier’s Pharma Insight Briefing on the latest development in Aptar Pharma’s Premium Injectables portfolio will take place on Wednesday, October 25 at 10:30 at the Innopack Zone, G1A3.